R- 2- (3- N- (2- benzo(1,4)dioxanylmethyl)- amino- 1- propyl)- 3(2H)- pyridazinone hydrochloride
The combined alpha1- and postsynaptically selective alpha2-blocker GYKI-16084 significantly improved the AUA symptom scores and increased Q(max) in patients with BPH, without inducing any adverse reaction, orthostatic changes or erectile dysfunction
Also Known As:
GYKI-16084
Networked: 1
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts